A Randomized, Phase 1b Study to Investigate the Safety and Immunogenicity of Various Schedules of Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers Between the Ages of 18 - 45 Years
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2017
At a glance
- Drugs TAK 003 (Primary)
- Indications Dengue
- Focus Adverse reactions; Therapeutic Use
- Sponsors Inviragen
- 08 Jan 2015 Protocol has been amended in addition of primary endpoints and change of trial focus from AE to AE and TU.
- 08 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 17 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.